Lucid Diagnostics Inc. LUCD 深 滬
已收盤 01-09 16:00:00 美东时间
1.18
-0.050
-4.07%
華盛通- 最 高1.2399
- 今 開1.23
- 成交量 49.02万股
- 最 低 1.16
- 昨 收 1.23
- 總市值 1.55亿
- 52周最高 1.80
- 市盈率 靜 --
- 換手率 0.37%
- 52周最低 0.8107
- 委 比 58.08%
- 總股本 1.31亿
- 歷史最高 13.52
- 量 比 0.78
- 振 幅 6.50%
- 歷史最低 0.6301
- 每 手 1
- 風險率 0.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多PAVmed Announces Reverse Stock Split
NEW YORK, Dec. 30, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, di...
2025-12-30 22:01
美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
2025-12-11 10:33
Lucid Diagnostics Files Prospectus To Raise Up To $175M Through Sale Of Stock, Debt And Warrants
Lucid Diagnostics Inc. $175,000,000 Common Stock, Preferred Stock, Debt Securities, Warrants and Units We may offer and sell from time to time shares of common stock, shares of preferred stock, debt
2025-12-06 06:09
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
Needham Reiterates Buy on Lucid Diagnostics, Maintains $3 Price Target
Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $3 price target.
2025-11-13 19:00
Lucid Diagnostics Q3 Adj. EPS $(0.10) Beats $(0.11) Estimate, Sales $1.211M Miss $1.357M Estimate
Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 50 percent increase over losses of $(0.20) per share from the
2025-11-12 21:09
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
2025-11-12 19:11
美股大行评级 | 潜在涨幅4347.41%！Ascendiant Capital上调PAVmed目标价至20美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从19美元升至20美元；Ascendiant Capital：维持Plus Therapeutics"买入"评级，目标价从20.5美元升至21美元
2025-10-07 15:04
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $8
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $7.75 to $8.
2025-10-06 18:06
Lucid Diagnostics Appoints John R. Palumbo to Board
The latest announcement is out from Lucid Diagnostics ( ($LUCD) ). On September...
2025-09-25 21:17
